國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

HCVthe journey from discovery to a c...

Sofia, Michael J.

HCVthe journey from discovery to a cure.Volume II /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	HCVedited by Michael J. Sofia.
其他題名:	the journey from discovery to a cure.
其他作者:	Sofia, Michael J.
出版者:	Cham :Springer International Publishing :2019.
面頁冊數:	viii, 500 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Hepatitis CTreatment.
電子資源:	https://doi.org/10.1007/978-3-030-28400-8
ISBN:	9783030284008$q(electronic bk.)

HCVthe journey from discovery to a cure.Volume II /
HCVthe journey from discovery to a cure.Volume II /[electronic resource] :edited by Michael J. Sofia. - Cham :Springer International Publishing :2019. - viii, 500 p. :ill., digital ;24 cm. - Topics in medicinal chemistry,321862-2461 ;. - Topics in medicinal chemistry ;8..

NS5A as a target for HCV Drug Discovery -- The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex -- The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni® -- The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa® and Vosevi® -- Discovery of Elbasvir -- HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments -- Evolution of HCV NS4B Inhibitors -- The Evolution of Clinical Trials for Hepatitis C -- The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®) -- The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa®) -- The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi®) -- Clinical Development of Viekira Pak to Mavyret -- Development of ZEPATIER® -- Real world effectiveness of DAA therapies -- The Benefit of Direct-Acting Antiviral HCV Cure Therapies -- Cure and Control: What Will It Take to Eliminate HCV? -- Perspectives on HCV Cure.

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume I".

ISBN: 9783030284008$q(electronic bk.)

Standard No.: 10.1007/978-3-030-28400-8doiSubjects--Topical Terms:

558961
Hepatitis C
--Treatment.

LC Class. No.: RC848.H425

Dewey Class. No.: 616.3623

HCVthe journey from discovery to a cure.Volume II /
LDR:03573nmm a2200337 a 4500 001 570824
003 DE-He213
005 20200429110646.0
006 m d
007 cr nn 008maaau
008 200902s2019 sz s 0 eng d
020 $a 9783030284008$q(electronic bk.)
020 $a 9783030283995$q(paper)
024 7 $a 10.1007/978-3-030-28400-8 $2 doi
035 $a 978-3-030-28400-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RC848.H425
072 7 $a PSB $2 bicssc
072 7 $a SCI013020 $2 bisacsh
072 7 $a PSB $2 thema
082 0 4 $a 616.3623 $2 23
090 $a RC848.H425 $b H431 2019
245 0 0 $a HCV $h [electronic resource] : $b the journey from discovery to a cure. $n Volume II / $c edited by Michael J. Sofia.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a viii, 500 p. : $b ill., digital ; $c 24 cm.
490 1 $a Topics in medicinal chemistry, $x 1862-2461 ; $v 32
505 0 $a NS5A as a target for HCV Drug Discovery -- The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex -- The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni® -- The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa® and Vosevi® -- Discovery of Elbasvir -- HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments -- Evolution of HCV NS4B Inhibitors -- The Evolution of Clinical Trials for Hepatitis C -- The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®) -- The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa®) -- The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi®) -- Clinical Development of Viekira Pak to Mavyret -- Development of ZEPATIER® -- Real world effectiveness of DAA therapies -- The Benefit of Direct-Acting Antiviral HCV Cure Therapies -- Cure and Control: What Will It Take to Eliminate HCV? -- Perspectives on HCV Cure.
520 $a Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide. This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume I".
650 0 $a Hepatitis C $x Treatment. $3 558961
650 0 $a Hepatitis C virus. $3 274259
650 1 4 $a Medicinal Chemistry. $3 275183
650 2 4 $a Virology. $3 196498
650 2 4 $a Medical Biochemistry. $3 274286
650 2 4 $a Bioorganic Chemistry. $3 275016
650 2 4 $a Pharmaceutical Sciences/Technology. $3 338426
700 1 $a Sofia, Michael J. $3 855300
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Topics in medicinal chemistry ; $v 8. $3 567153
856 4 0 $u https://doi.org/10.1007/978-3-030-28400-8
950 $a Chemistry and Materials Science (Springer-11644)